RxDoctor Payments Data

Jason Hade, MD

Ophthalmology · Denville, NJNPI 1497929509

Payments from drug & device makers

$2,386in general payments, 2019–2025

Across 24 payments — averaging $99.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Glaukos Corporation$283
  • AbbVie$180
  • Bausch & Lomb Americas Inc.$174
  • Aerie Pharmaceuticals, Inc.$98
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$40
  • plus $40 from 3 others

What the payments were for

  • Travel & lodging$1,27653%
  • Food & beverage$1,11047%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,386 in reported general payments places this provider in the 60th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$206,583
Medicare patients
877
Services billed
1,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine71$59,071
MieboPerfluorohexyloctane/Pf58$48,247
LumiganBimatoprost78$40,670
VyzultaLatanoprostene Bunod49$26,478
CombiganBrimonidine Tartrate/Timolol48$22,945
RocklatanNetarsudil Mesylat/Latanoprost36$20,956
XiidraLifitegrast14$16,954
Cyclosporine40$14,598
RhopressaNetarsudil Mesylate22$9,477
Alphagan PBrimonidine Tartrate21$6,232
Bimatoprost21$3,785
Dorzolamide-TimololDorzolamide/Timolol/Pf19$2,833
Fluorometholone27$2,824
Brimonidine Tartrate73$2,639
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$180$128,918218 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta, Xiidra$174$91,678121 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$98$30,43358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Denville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →